From ASCO 2023 Annual Meeting:
Survival outcomes for persistent, recurrent or metastatic cervical cancer are significantly improved with the use of pembrolizumab alongside chemotherapy, regardless of bevacizumab therapy
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.